The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
OXERVATE (JACE Pharma Pty Ltd)
Product name
OXERVATE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
181 working days (255)
Active ingredients
cenegermin (rbe)
Registration type
NCE/NBE
Indication
OXERVATE (eye drops) is indicated for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.